This is the development pipeline as of Jan 23, 2023
1. Oncology (OPDIVO)
As of Jan 23, 2023
| Product name or Development code (Generic name) |
Mechanism | Target disease | Development stage |
Country/ Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F i l i n g |
A p p r o v a l |
|||||
| Opdivo Intravenous Infusion (Nivolumab) |
Anti-PD-1 antibody | Melanoma (2nd) |
|
JP・KR・TW | In-house (Co-developed with BMS) |
||||
| Melanoma (1st) |
|
JP・KR・TW | |||||||
| Melanoma (Adjuvant therapy) |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer (2nd～) |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer (1st) |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer (Neoadjuvant therapy) |
|
KR | |||||||
|
|
JP | ||||||||
|
|
TW | ||||||||
| Renal cell carcinoma (2nd～) |
|
JP・KR・TW | |||||||
| Renal cell carcinoma (1st) |
|
JP・KR・TW | |||||||
| Hodgkin’s lymphoma |
|
JP・KR・TW | |||||||
| Hodgkin's lymphoma (Pediatric) |
|
JP | |||||||
| Head and neck cancer |
|
JP・KR・TW | |||||||
| Gastric cancer (3rd) |
|
JP・KR・TW | |||||||
| Gastric cancer (1st) |
|
JP・KR・TW | |||||||
| Malignant pleural mesothelioma (SOC refractory) |
|
JP | |||||||
| Malignant pleural mesothelioma (1st) |
|
JP・KR・TW | |||||||
| Colorectal cancer (MSI-High) |
|
JP・KR・TW | |||||||
| Esophageal cancer (2nd) |
|
JP・KR・TW | |||||||
| Esophageal cancer (1st) |
|
JP・TW | |||||||
|
|
KR | ||||||||
| Esophageal cancer (Adjuvant therapy) |
|
JP・KR・TW | |||||||
| Urothelial cancer/Bladder cancer (2nd) |
|
JP | |||||||
|
|
KR・TW | ||||||||
| Urothelial cancer/Bladder cancer (Adjuvant therapy) |
|
JP・KR・TW | |||||||
| Urothelial cancer/Bladder cancer(Perioperative) |
|
JP・KR・TW | |||||||
| Urothelial cancer/Bladder cancer(1st) |
|
JP・KR・TW | |||||||
| Cancer of unknown primary |
|
JP | |||||||
| Hepatocellular carcinoma (Adjuvant therapy) |
|
JP・KR・TW | |||||||
| Hepatocellular carcinoma (1st) |
|
JP・KR・TW | |||||||
| Hepatocellular carcinoma (2nd) |
|
TW | |||||||
|
|
JP・KR | ||||||||
| Ovarian cancer |
|
JP・KR・TW | |||||||
| Prostate cancer |
|
JP・KR・TW | |||||||
2. Oncology (Other than OPDIVO)
As of Jan 23, 2023
| Product name or Development code (Generic name) |
Mechanism | Target disease | Development stage |
Country/ Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F i l i n g |
A p p r o v a l |
|||||
| Yervoy Injection★ (Ipilimumab) |
Anti-CTLA-4 antibody | Melanoma |
|
JP・KR・TW | BMS | ||||
| Renal cell carcinoma |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer |
|
JP・KR・TW | |||||||
| Colorectal cancer (MSI-High) |
|
JP・KR・TW | |||||||
| Malignant pleural mesothelioma |
|
JP・KR・TW | |||||||
| Esophageal cancer |
|
JP・TW | |||||||
|
|
KR | ||||||||
| Gastric cancer |
|
JP・KR・TW | |||||||
| Urothelial cancer |
|
JP・KR・TW | |||||||
| Hepatocellular carcinoma |
|
JP・KR・TW | |||||||
| Velexbru Tablets (Tirabrutinib Hydrochloride) |
Bruton‘s tyrosine kinase (BTK) inhibitor | Primary central nervous system lymphoma |
|
JP・KR・TW | In-house | ||||
|
|
US | ||||||||
| Primary macroglobulinemia Lymphoplasmacytic lymphoma |
|
JP | |||||||
| Adlumiz Tablets (Anamorelin Hydrochloride) |
Ghrelin mimetic | Cancer cachexia |
|
JP | Helsinn | ||||
| Braftovi Capsules (Encorafenib) |
BRAF inhibitor | Melanoma (BRAF-mutation positive) |
|
JP | Pfizer | ||||
| Colorectal cancer (BRAF-mutation positive) |
|
JP・KR | |||||||
| Thyroid cancer (BRAF-mutation positive) |
|
JP | |||||||
| Mektovi Tablets (Binimetinib) |
MEK inhibitor | Melanoma (BRAF-mutation positive) |
|
JP | Pfizer | ||||
| Colorectal cancer (BRAF-mutation positive) |
|
JP | |||||||
| Thyroid cancer (BRAF-mutation positive) |
|
JP | |||||||
| Kyprolis for Intravenous Infusion (Carfilzomib) |
Proteasome inhibitor | Multiple myeloma |
|
JP | Amgen | ||||
| ONO-7913 (Magrolimab) |
Anti-CD47 antibody | TP53-mutant Acute myeloid leukemia |
|
JP | Gilead | ||||
| Acute myeloid leukemia |
|
KR・TW | |||||||
| Solid tumor |
|
JP | |||||||
| Myelodysplastic syndrome |
|
JP | |||||||
| Pancreatic cancer★ |
|
JP | |||||||
| Colorectal cancer★ |
|
JP | |||||||
| ONO-4686 ★ | Anti-TIGIT antibody | Solid tumor |
|
JP | BMS | ||||
| ONO-4482★ (Relatlimab) | Anti-LAG-3 antibody | Melanoma |
|
JP | BMS | ||||
| ONO-7475 | Axl/Mer inhibitor | Solid tumor★ |
|
JP | In-house | ||||
| EGFR-mutated non-small cell lung cancer |
|
JP | |||||||
| ONO-4578 | PG receptor (EP4) antagonist | Solid tumor・Gastric cancer★ |
|
JP | In-house | ||||
| Colorectal cancer★ |
|
JP | |||||||
| Pancreatic cancer★ |
|
JP | |||||||
| Non-small cell lung cancer★ |
|
JP | |||||||
| Hormone receptor-positive, HER2-negative breast cancer |
|
JP | |||||||
| ONO-7119★ (Atamparib) |
PARP7 inhibitor | Solid tumor |
|
JP | Ribon | ||||
| ONO-7122★ | TGF-β inhibitor | Solid tumor |
|
JP | BMS | ||||
| ONO-7914★ | STING agonist | Solid tumor |
|
JP | In-house | ||||
| ONO-4685 | PD-1×CD3 bispecific antibody | T-cell lymphoma |
|
US | In-house | ||||
| ONO-7018 | MALT1 Inhibitor | Non-Hodgkin lymphoma, chronic lymphocytic leukemia |
|
US | Chordia | ||||
★Combination with Opdivo.
3. Areas other than Oncology
As of Jan 23, 2023
| Product name or Development code (Generic name) |
Mechanism | Target disease | Development stage |
Country/ Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F i l i n g |
A p p r o v a l |
|||||
| Coralan Tablets (Ivabradine Hydrochloride) |
HCN channel blocker | Chronic heart failure |
|
JP | Servier | ||||
| Ongentys Tablets (Opicapone) |
Long acting COMT inhibitor | Parkinson’s disease |
|
JP | Bial | ||||
| Onoact for Intravenous Infusion (Landiolol Hydrochloride) |
Short-active selective β1 blocker | Tachyarrhythmia associated with sepsis |
|
JP | In-house | ||||
| Tachyarrhythmia in low cardiac function (Pediatric) |
|
JP | |||||||
| Orencia SC (Abatacept ) |
T-cell activation inhibitor | Rheumatoid arthritis (Prevention of structural damage of joints) |
|
JP | BMS | ||||
| Joyclu Intra-articular Injection (Diclofenac Etalhyaluronate Sodium) |
Hyaluronic acid-NSAID | Osteoarthritis (hip,knee) |
|
JP | Seikagaku | ||||
| ONO-2017 (Cenobamate) |
Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel | Primary generalized tonic-clonic seizures |
|
JP | SKBP | ||||
| Partial-onset seizures |
|
JP | |||||||
| Velexbru Tablets (Tirabrutinib Hydrochloride) |
Bruton's tyrosine kinase (BTK) inhibitor | Pemphigus |
|
JP | In-house | ||||
| Generalized scleroderma |
|
JP | |||||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Diabetic polyneuropathy |
|
JP | In-house | ||||
| ONO-4685 | PD-1×CD3 bispecific antibody | Autoimmune disease |
|
JP・EU | In-house | ||||
| ONO-2808 | S1P5 receptor agonist | Neurodegenerative disease |
|
JP・EU | In-house | ||||
| ONO-1110 | Endocannabinoid regulation | Pain |
|
JP | In-house | ||||
| ONO-7684 | FXIa inhibitor | Thrombosis |
|
JP・EU | In-house | ||||
| ONO-2020 | Epigenetic Regulation | Neurodegenerative disease |
|
US | In-house | ||||